Pharmachal Closes Round 1 of Capital Raise

Over $250,000 raised

This article is from Unspecified for Health Care, Medical & Biotech

"Pharmachal Health Group (“PHG” or “Company”) is pleased to announce the achievement of Round 1 of the capital raise is fully subscribed with approx. $250k raised, enabling the Company to secure a >90% holding of NS Technologies, the related-party development company holding the internationally certified patents for the proprietary Nano Drug Delivery System (“NDDS”). 

The capital has also assisted in the Company to initiate the last commercial-scale batch of NOPAYNE Spray, the final requirement before submission to the TGA for registration. 

The three new over-the-counter dermal products, including a physio cream, a foot cream and a eucalyptus-honey ointment, are currently with the contract manufacturer’s planning division, which is acquiring all the ingredients and packaging to enable the products to be manufactured. These products will be available for domestic and international sale in as few as six to eight weeks. Charles Fridlender Director 14 April"

Related Attachments

April 14th, 2021

Pharmachal Announcement 14 April 2021 ( 140.16 KB )

Related News & Products

  • PHG has secured a >90% holding of NS Technologies
    March 31st, 2021
    PHG has secured a >90% holding of NS Technologies